Phase II and Biologic Study of Interferon Alfa, Retinoic Acid, and Cisplatin in Advanced Squamous Skin Cancer

医学 中性粒细胞减少症 内科学 顺铂 胃肠病学 毒性 白细胞减少症 进行性疾病 化疗 α-干扰素 临床研究阶段 癌症 外科 肿瘤科 免疫疗法
作者
Dong M. Shin,Bonnie S. Glisson,Fadlo R. Khuri,John L. Clifford,Gary L. Clayman,Steven E. Benner,Arlene A. Forastiere,Lawrence E. Ginsberg,Diane Liu,J. Jack Lee,Jeffrey N. Myers,Helmuth Goepfert,Reuben Lotan,Waun Ki Hong,Scott M. Lippman
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:20 (2): 364-370 被引量:96
标识
DOI:10.1200/jco.2002.20.2.364
摘要

PURPOSE: The purpose of this study was to test interferon alfa (IFNα), 13-cis-retinoic acid (13cRA), and cisplatin biochemotherapy in advanced squamous cell carcinoma (SCC) of the skin. PATIENTS AND METHODS: Patients with advanced skin SCC received IFNα (5 × 10 6 IU/m 2 , subcutaneous injection, three times a week), 13cRA (1 mg/kg, orally, daily), and cisplatin (20 mg/m 2 , intravenous injection, weekly) in a phase II trial. The growth inhibition, cell-cycle, and apoptosis activity of these agents was evaluated in two skin SCC cell lines (SRB1-m7 and SRB12-p9). RESULTS: Thirty-nine patients were enrolled. All were assessable for survival, 35 for response and toxicity (median follow-up was 38 months). The overall and complete response rates were 34% and 17%, respectively, with median durations of 9 and 35.4 months, respectively. The response rate was higher in locally advanced (67%) than metastatic (17%) disease (P = .007). Median survival was 14.6 months. One-, 2-, and 5-year survival rate estimates were 58%, 32%, and 21%, respectively. Toxicity included generally mild to moderate fatigue and mucocutaneous dryness, moderate to severe neutropenia (38%), and neutropenic fever (6%). There were no treatment-related deaths. In vitro growth inhibition and apoptosis effects of cisplatin were differential and inversely associated with those of retinoic acid and especially IFNα in two skin SCC lines. CONCLUSION: The rising incidence, morbidity, and mortality of advanced skin SCC are a major challenge for clinical oncologists. Combined 13cRA, IFNα, and cisplatin was clinically active in extensive locally advanced disease. Each agent had independent, non–cross-resistant biologic effects in vitro, which may account for the combination’s clinical activity.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3应助写得出发的中采纳,获得30
刚刚
fgh发布了新的文献求助10
1秒前
1234完成签到,获得积分10
1秒前
1秒前
自然初露完成签到 ,获得积分10
2秒前
3秒前
KingXing发布了新的文献求助10
3秒前
TH1223完成签到,获得积分10
3秒前
bei完成签到 ,获得积分10
4秒前
Bio应助混子小高采纳,获得30
4秒前
yao学渣完成签到 ,获得积分10
5秒前
不二臣发布了新的文献求助10
6秒前
可爱的函函应助kkk采纳,获得10
6秒前
斯文败类应助偷乐采纳,获得10
6秒前
Ava应助mariawang采纳,获得10
7秒前
girl发布了新的文献求助10
7秒前
orixero应助szl采纳,获得10
7秒前
自然初露关注了科研通微信公众号
8秒前
yu完成签到 ,获得积分10
8秒前
KingXing完成签到,获得积分10
9秒前
粗犷的灵松完成签到 ,获得积分10
9秒前
yyyyy关注了科研通微信公众号
11秒前
小姚发布了新的文献求助10
11秒前
wjw完成签到,获得积分10
12秒前
12秒前
毛小驴完成签到,获得积分10
13秒前
谢俏艳完成签到,获得积分10
13秒前
lm发布了新的文献求助10
13秒前
13秒前
13秒前
852应助咕噜咕噜咕嘟咕嘟采纳,获得10
14秒前
14秒前
小哥门完成签到,获得积分10
15秒前
Puan发布了新的文献求助10
15秒前
15秒前
sylnd126发布了新的文献求助10
16秒前
17秒前
峥2发布了新的文献求助10
17秒前
17秒前
吵吵robot发布了新的文献求助10
17秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988786
求助须知:如何正确求助?哪些是违规求助? 3531116
关于积分的说明 11252493
捐赠科研通 3269766
什么是DOI,文献DOI怎么找? 1804771
邀请新用户注册赠送积分活动 881870
科研通“疑难数据库(出版商)”最低求助积分说明 809021